Together, these results suggest that NAFLD does not inhibit tumor antigen production or the generation of tumor antigen-specific CD8+ T cells, yet these TAS T cells fail to control tumor. This evidence concerns the gene CD8A and metabolic dysfunction-associated steatotic liver disease.